12-month effects of incretins versus SGLT2-Inhibitors on cognitive performance and metabolic profile. A randomized clinical trial in the elderly with Type-2 diabetes mellitus

References

• KodlCTSeaquistERCognitive dysfunction and diabetes mellitusEndocr Rev200829449451118436709
   PubMed Web of Science ®Google Scholar
• SaediEGheiniMRFaizFAramiMADiabetes mellitus and cognitive impairmentsWorld J Diabetes201671741242227660698
   PubMed Web of Science ®Google Scholar
• OttAStolkRPvan HarskampFPolsHAHofmanABretelerMMDiabetes mellitus and the risk of dementia: The Rotterdam StudyNeurology19995391937194210599761
   PubMed Web of Science ®Google Scholar
• LeibsonCLRoccaWAHansonVARisk of dementia among persons with diabetes mellitus: a population-based cohort studyAm J Epidemiol199714543013089054233
   PubMed Web of Science ®Google Scholar
• OjoOBrookeJEvaluating the Association between Diabetes, Cognitive Decline and DementiaInt J Environ Res Public Health20151278281829426193295
   PubMed Web of Science ®Google Scholar
• ZillioxLAChadrasekaranKKwanJYRussellJWDiabetes and Cognitive ImpairmentCurr Diab Rep20161698727491830
   PubMed Web of Science ®Google Scholar
• CukiermanTGersteinHCWilliamsonJDCognitive decline and dementia in diabetes—systematic overview of prospective observational studiesDiabetologia200548122460246916283246
   PubMed Web of Science ®Google Scholar
• NandipatiSLuoXSchimmingCGrossmanHTSanoMCognition in non-demented diabetic older adultsCurr Aging Sci20125213113522023096
   PubMedGoogle Scholar
• Cukierman-YaffeTGersteinHCWilliamsonJDAction to Control Cardiovascular Risk in Diabetes-Memory in Diabetes (ACCORD-MIND) Investigators). Relationship Between Baseline Glycemic Control and Cognitive Function in Individuals With Type 2 Diabetes and Other Cardiovascular Risk Factors. The Action to Control Cardiovascular Risk in Diabetes-Memory in Diabetes (ACCORD-MIND) trialDiabetes Care200932222122619171735
   PubMed Web of Science ®Google Scholar
• MeneillyGSCheungETessierDYakuraCTuokkoHThe effect of improved glycemic control on cognitive functions in the elderly patient with diabetesJ Gerontol1993484M117M1218315222
   PubMedGoogle Scholar
• WhitmerRAType 2 diabetes and risk of cognitive impairment and dementiaCurr Neurol Neurosci Rep20077537338017764626
   PubMed Web of Science ®Google Scholar
• UmegakiHType 2 diabetes as a risk factor for cognitive impairment: current insightsClin Interv Aging201491011101925061284
   PubMed Web of Science ®Google Scholar
• StrachanMWReynoldsRMMarioniREPriceJFCognitive function, dementia and type 2 diabetes mellitus in the elderlyNat Rev Endocrinol20117210811421263438
   PubMed Web of Science ®Google Scholar
• HolstJJVilsbøllTDeaconCFThe incretin system and its role in type 2 diabetes mellitusMol Cell Endocrinol20092971–212713618786605
   PubMed Web of Science ®Google Scholar
• HolstJJGromadaJRole of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humansAm J Physiol Endocrinol Metab20042872E19920615271645
   PubMed Web of Science ®Google Scholar
• DruckerDJThe biology of incretin hormonesCell Metab20063315316516517403
   PubMed Web of Science ®Google Scholar
• DeaconCFMannucciEAhrénBGlycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysisDiabetes Obes Metab201214876276722471248
   PubMed Web of Science ®Google Scholar
• Abd El AzizMSKahleMMeierJJNauckMAA meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patientsDiabetes Obes Metab201719221622727717195
   PubMed Web of Science ®Google Scholar
• RondanelliMPernaSAstronePGrugnettiASolerteSBGuidoDTwenty-four-week effects of liraglutide on body composition, adherence to appetite, and lipid profile in overweight and obese patients with type 2 diabetes mellitusPatient Prefer Adherence20161040741327069358
   PubMed Web of Science ®Google Scholar
• KoliakiCDoupisJIncretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitusDiabetes Ther20112210112122127804
   PubMedGoogle Scholar
• RizzoMRBarbieriMBoccardiVAngellottiEMarfellaRPaolissoGDipeptidyl peptidase-4 inhibitors have protective effect on cognitive impairment in aged diabetic patients with mild cognitive impairmentJ Gerontol A Biol Sci Med Sci20146991122113124671867
   PubMed Web of Science ®Google Scholar
• IsikATSoysalPYayAUsarelCThe effects of sitagliptin, a DPP-4 inhibitor, on cognitive functions in elderly diabetic patients with or without Alzheimer’s diseaseDiabetes Res Clin Pract201712319219828056430
   PubMed Web of Science ®Google Scholar
• MosselloEBalliniEBoncinelliMGlucagon-like peptide-1, diabetes, and cognitive decline: possible pathophysiological links and therapeutic opportunitiesExp Diabetes Res2011201128167421747826
   PubMedGoogle Scholar
• HamiltonAPattersonSPorterDGaultVAHolscherCNovel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brainJ Neurosci Res201189448148921312223
   PubMed Web of Science ®Google Scholar
• PorterDWKerrBDFlattPRHolscherCGaultVAFour weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistanceDiabetes Obes Metab2010121089189920920042
   PubMed Web of Science ®Google Scholar
• KalraSSodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical PharmacologyDiabetes Ther20145235536625424969
   PubMed Web of Science ®Google Scholar
• Abdul-GhaniMADefronzoRALowering plasma glucose concentration by inhibiting renal sodium-glucose cotransportJ Intern Med2014276435236324690096
   PubMed Web of Science ®Google Scholar
• NairSWildingJPSodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitusJ Clin Endocrinol Metab2010951344219892839
   PubMed Web of Science ®Google Scholar
• ZaccardiFWebbDRHtikeZZYoussefDKhuntiKDaviesMJEfficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysisDiabetes Obes Metab201618878379427059700
   PubMed Web of Science ®Google Scholar
• FerranniniESoliniASGLT2 inhibition in diabetes mellitus: rationale and clinical prospectsNat Rev Endocrinol20128849550222310849
   PubMed Web of Science ®Google Scholar
• ScheenAJPharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitusDrugs2015751335925488697
   PubMed Web of Science ®Google Scholar
• ZinmanBWannerCLachinJMEmpagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesN Engl J Med2015373222117212826378978
   PubMed Web of Science ®Google Scholar
• LinBKoibuchiNHasegawaYGlycemic control with empa-gliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic miceCardiovasc Diabetol20141314825344694
   PubMed Web of Science ®Google Scholar
• American Psychiatric AssociationDiagnostic and statistical manual of mental disorders (DSM-5®5thAmerican Psychiatric Pub2013
   Google Scholar
• FolsteinMFFolsteinSEMchughPR“Mini-mental state”. A practical method for grading the cognitive state of patients for the clinicianJ Psychiatr Res19751231891981202204
   PubMed Web of Science ®Google Scholar
• GrigolettoFZappalàGAndersonDWLebowitzBDNorms for the Mini-Mental State Examination in a healthy populationNeurology199953231532010430420
   PubMed Web of Science ®Google Scholar
• FrisanchoARNew standards of weight and body composition by frame size and height for assessment of nutritional status of adults and the elderlyAm J Clin Nutr19844048088196486088
   PubMed Web of Science ®Google Scholar
• SpinnlerHTognoniGStandardizzazione e taratura italiana di test neuropsicologici [Standardization and Italian setting of mental test]Ital J Neurol Sci1987Suppl 821120 Italian3654177
   PubMedGoogle Scholar
• AbbateCLuzzattiCVerganiCMatrix test: speed and accuracy of visual search in agingG Gerontol2007551120
   Google Scholar
• NovelliGPapagnoCCapitaniELaiaconaNVallarGCappaSFTre test clinici di ricerca e produzione lessicale [three clinical test in scientific production]. Taratura su soggetti normaliArchivio di Psicologia, Neurologia e Psichiatria1986474477506 Italian
   Google Scholar
• HornerMDTeichnerGKortteKBHarveyRTConstruct validity of the Babcock Story Recall TestAppl Neuropsychol20029211411612214822
   PubMedGoogle Scholar
• RizviSMShakilSBiswasDInvokana (Canagliflozin) as a dual inhibitor of acetylcholinesterase and sodium glucose co-transporter 2: advancement in Alzheimer’s disease- diabetes type 2 linkage via an enzo-informatics studyCNS Neurol Disord Drug Targets201413344745124059302
   PubMed Web of Science ®Google Scholar
• ArafaNMMarieMAAlazimiSAEffect of canagliflozin and metformin on cortical neurotransmitters in a diabetic rat modelChem Biol Interact2016258798827566243
   PubMed Web of Science ®Google Scholar
• ShaikhSRizviSMShakilSRiyazSBiswasDJahanRForxiga (dapagliflozin): Plausible role in the treatment of diabetes-associated neurological disordersBiotechnol Appl Biochem201663114515025402624
   PubMed Web of Science ®Google Scholar
• ChenSSunJZhaoGLiraglutide Improves Water Maze Learning and Memory Performance While Reduces Hyperphosphorylation of Tau and Neurofilaments in APP/PS1/Tau Triple Transgenic MiceNeurochem Res20174282326233528382596
   PubMed Web of Science ®Google Scholar
• PalleriaCLeoAAndreozziFLiraglutide prevents cognitive decline in a rat model of streptozotocin-induced diabetes independently from its peripheral metabolic effectsBehav Brain Res201732115716928062257
   PubMed Web of Science ®Google Scholar
• KambleMGuptaRRehanHSGuptaLKNeurobehavioral effects of liraglutide and sitagliptin in experimental modelsEur J Pharmacol2016774647026849938
   PubMed Web of Science ®Google Scholar
• KosarajuJMurthyVKhatwalRBVildagliptin: an anti-diabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin-induced Alzheimer’s diseaseJ Pharm Pharmacol201365121773178424117480
   PubMed Web of Science ®Google Scholar
• El BatshMMEl BatchMMShafikNMYounosIHFavorable effects of vildagliptin on metabolic and cognitive dysfunctions in streptozotocin-induced diabetic ratsEur J Pharmacol201576929730526607467
   PubMed Web of Science ®Google Scholar
• PintanaHApaijaiNChattipakornNChattipakornSCDPP-4 inhibitors improve cognition and brain mitochondrial function of insulin-resistant ratsJ Endocrinol2013218111123591914
   PubMed Web of Science ®Google Scholar
• TsaiTHSunCKSuCHChSSitagliptin attenuated brain damage and cognitive impairment in mice with chronic cerebral hypo-perfusion through suppressing oxidative stress and inflammatory reactionJ Hypertens20153351001101325689400
   PubMed Web of Science ®Google Scholar
• GaultVALennoxRFlattPRSitagliptinFPRSitagliptin, a dipeptidyl peptidase-4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive declineDiabetes Obes Metab201517440341325580570
   PubMed Web of Science ®Google Scholar
• TasciINaharciMIBozogluECognitive and functional influences of vildagliptin, a DPP-4 inhibitor, added to ongoing metformin therapy in elderly with type 2 diabetesEndocr Metab Immune Disord Drug Targets201313325626323848558
   PubMed Web of Science ®Google Scholar
• DuringMJCaoLZuzgaDSGlucagon-like peptide-1 receptor is involved in learning and neuroprotectionNat Med2003991173117912925848
   PubMed Web of Science ®Google Scholar
• MccleanPLGaultVAHarriottPHölscherCGlucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer’s diseaseEur J Pharmacol20106301–315816220035739
   PubMed Web of Science ®Google Scholar
• MonamiMDicembriniIMannucciEEffects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trialsActa Diabetol2017541193627488726
   PubMed Web of Science ®Google Scholar
• ChaoECHenryRRSGLT2 inhibition--a novel strategy for diabetes treatmentNat Rev Drug Discov20109755155920508640
   PubMed Web of Science ®Google Scholar
• SehgalVBajwaSJSehgalRConsalvoJAManagement of diabetes in the elderly with canagliflozin: A newer hypoglycemic drug on the horizonJ Pharmacol Pharmacother20145422723125422561
   PubMedGoogle Scholar
• ListJFWooVMoralesETangWFiedorekFTSodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetesDiabetes Care200932465065719114612
   PubMed Web of Science ®Google Scholar
• MadsbadSReview of head-to-head comparisons of gluca-gon-like peptide-1 receptor agonistsDiabetes Obes Metab201618431733226511102
   PubMed Web of Science ®Google Scholar
• ShyangdanDSRoylePClarCSharmaPWaughNSnaithAGlucagon-like peptide analogues for type 2 diabetes mellitus.Cochrane Database Syst Rev201110CD006423
   PubMed Web of Science ®Google Scholar
• DunganKMPovedanoSTForstTOnce-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trialLancet201438499511349135725018121
   PubMed Web of Science ®Google Scholar
• NauckMAFriedrichNDo GLP-1-based therapies increase cancer risk?Diabetes Care201336Suppl 2S24525223882053
   PubMed Web of Science ®Google Scholar
• DoreDDSeegerJDArnold ChanKUse of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburideCurr Med Res Opin20092541019102719278373
   PubMed Web of Science ®Google Scholar